Latest Biotechnology News

Argenica Therapeutics has won up to $1.5 million in non-dilutive government funding to support its late-stage clinical trial of ARG-007, a promising treatment for acute ischaemic stroke.

Zoono Group Limited is raising nearly $1.8 million through a non-renounceable rights issue to fund its supermarket shelf-life extension project in Asia and reduce related party debt.

Neurizon Therapeutics reveals that its lead drug candidate NUZ-001 and its metabolite effectively penetrate the blood-brain barrier and reverse pathological protein aggregation linked to ALS, marking a critical step forward in neurodegenerative disease treatment.

INOVIQ Limited has announced a breakthrough in its cancer treatment program, with its CAR-exosome therapy killing 88% of triple negative breast and lung cancer cells in laboratory studies. This innovation could pave the way for faster, safer, and more accessible cancer therapies.

Patrys Limited has formalized the redundancy of CEO Dr James Campbell, with a $535,877 payout partly converted into shares pending shareholder approval. Dr Campbell will continue as a non-executive director.

RLF AgTech has secured exclusive rights to distribute AXIOMA Biologicals’ advanced biostimulant products across Australia, China, and Asia, marking a strategic move into the biologicals market segment.

Nyrada’s Phase I clinical trial for its novel drug Xolatryp has cleared safety reviews through four cohorts and will now test higher doses and longer infusions in an expanded trial design.

AdAlta Limited has successfully placed the remaining shortfall in its renounceable rights issue, raising a total of $1.3 million to advance its cellular immunotherapy pipeline. The company also addressed an administrative breach involving director share allocations, ensuring compliance with ASX rules.

AnteoTech secures a significant purchase order from the Serum Institute of India, driving its Life Sciences unit toward a projected 130% sales increase in FY2025 despite some project delays.

AdNeo Limited’s shares are back on the ASX following the completion of a capital raising, ending a trading suspension that had investors waiting. The biotech company’s next moves will be closely watched as it seeks to leverage fresh funds.

Noxopharm’s Sofra™ technology has received promising external validation from BioRay Pharmaceutical, confirming its targeted anti-inflammatory potential and broad applicability in autoimmune disease therapies.

Invion Limited has addressed ASX queries over the timing and content of its cleansing notice, confirming encouraging early results from its Phase I/II non-melanoma skin cancer trial using Photosoft™ technology.